This page defines the modelling rules and description templates for Phase 1 only of the Canadian Medicines Terminology (CMT) project. Phase-specific content will be added as the project progresses.
Definition
The representation of a medicinal product supplied by a single organization (supplier) in Canada under a single product name, and which contains the same set of active ingredients and dose form. The active ingredients used to define a TMPF do not include any modification that is not either clinically significant or (if relevant) part of the product’s basis of strength substance.
Attributes
The TMPF uses the following defining attributes:
Attribute | Alias | Group | Card | G Card | D/O | Range |
373873005 |Count of base of active ingredient| | BCount | NO | 1..1 | 0..0 | DATA | Integer >#0.. |
127489000 |Has active ingredient| | AI | YES (1) | 0..* | 0..1 | OBJECT | < 105590001 |Substance| |
762949000 |Has precise active ingredient | PAI | YES (1) | 0..* | 0..1 | OBJECT | < 105590001 |Substance| |
732943007 |Has basis of strength substance| | BOSS | YES (1) | 0..* | 0..1 | OBJECT | < 105590001 |Substance| |
411116001|Has manufactured dose form| | MDF | NO | 0..1 | 0..0 | OBJECT | < 736542009 |Pharmaceutical dose form| |
774167006 |Product name| | ProdName | NO | 0..1 | 0..0 | OBJECT | < 774167006 |Product name| |
774164004 |Supplier| | Supplier | NO | 0..1 | 0..0 | OBJECT | < 774164004 |Supplier| |
Concepts
Up to two TMPF concepts are created for each DPD drug product. These are listed below.
TMPF-1 (mandatory)
The first TMPF concept must always be created (unless it already exists) for every DPD drug product and is defined using the following attributes:
Attribute | Alias | Group | Card | G Card | D/O | Range |
373873005 |Count of base of active ingredient| | BCount | NO | 1..1 | 0..0 | DATA | Integer >#0.. |
127489000 |Has active ingredient| | AI | YES (1) | 0..* | 0..1 | OBJECT | < 105590001 |Substance| |
411116001|Has manufactured dose form| | MDF | NO | 0..1 | 0..0 | OBJECT | < 736542009 |Pharmaceutical dose form| |
774167006 |Product name| | ProdName | NO | 0..1 | 0..0 | OBJECT | < 774167006 |Product name| |
774164004 |Supplier| | Supplier | NO | 0..1 | 0..0 | OBJECT | < 774164004 |Supplier| |
TMPF-2 (optional)
The second TMPF concept will only be created (unless it already exists) for each DPD drug product when:
BCount = 1 AND [0..0] TCD.BMCount (i.e. does not exist) AND BOSS <> AI
(i.e. single ingredient and BOSS <> AI)
and is defined using the following attributes:
Attribute | Alias | Group | Card | G Card | D/O | Range |
373873005 |Count of base of active ingredient| | BCount | NO | 1..1 | 0..0 | DATA | Integer >#0.. |
762949000 |Has precise active ingredient | PAI | YES (1) | 0..* | 0..1 | OBJECT | < 105590001 |Substance| |
732943007 |Has basis of strength substance| | BOSS | YES (1) | 0..* | 0..1 | OBJECT | < 105590001 |Substance| |
411116001|Has manufactured dose form| | MDF | NO | 0..1 | 0..0 | OBJECT | < 736542009 |Pharmaceutical dose form| |
774167006 |Product name| | ProdName | NO | 0..1 | 0..0 | OBJECT | < 774167006 |Product name| |
774164004 |Supplier| | Supplier | NO | 0..1 | 0..0 | OBJECT | < 774164004 |Supplier| |
Descriptions
TMPF generation of en-CA Fully Specified Name (FSN)
Format
TMPF-1 (mandatory)
[[ + @ProdName]]1 “ [“ [[ + @AI]]“ ” [[ + @MDF ]] “ ] (” [[ + @Supplier]]2 “) (real medicinal product form)” 3
TMPF-2 (optional)
[[ + @ProdName]]1 “ [“ [[ + @PAI 5 OR @BOSS 6]] [ “ (as ” [[ + @PAI ]] “)”] 5 “ ” [[ + @MDF ]] “ ] (” [[ + @Supplier]] 2 “) (real medicinal product form)” 3
TMPF generation of en-CA Preferred Term (PT)
Format
TMPF-1 (mandatory)
[[ + @ProdName]]1 “ [“ [[ + @AI]] “ ” [[ + @MDF ]] “ ] (” [[ + @Supplier]] 2 “)"4
TMPF-2 (optional)
[[ + @ProdName]]1 “ [“ [[ + @PAI 5 OR @BOSS 6]] [ “ (as ” [[ + @PAI ]] “)”] 5 “ ” [[ + @MDF ]] " ] (” [[ + @Supplier]] 2 “)" 4
Rules for English descriptions
1: ProdName is always fully capitalized
2: Supplier is always fully capitalized
3: For all attribute values, use the en-CA FSN with no semantic tag
4: For all attribute values, use the en-CA PT
5: PAI is used here when:
- BOSS is a modification of AI (direct or transitive)
- Note: In these cases, the PAI = TCD.BOSS
6: “BOSS (as PAI)” is used here when:
- BOSS is NOT a modification of AI (direct or transitive)
TMPF generation of fr-CA Fully Specified Name (FSN)
Format
TMPF-1 (mandatory)
[[ + @ProdName]]1 “ [“ [[ + @AI]] “ ” [[ + @MDF ]] “ ] (” [[ + @Supplier]] 2 “) (forme du produit médicinal commercial)”3
TMPF-2 (optional)
[[ + @ProdName]]1 “ [“ [[ + @PAI 5 OR @BOSS 6]] [ “ ( ” [[ + @PAI ]] “)”] 5“ ” [[ + @MDF ]] " ] (” [[ + @Supplier]] 2 “) (forme du produit médicinal commercial)” 3
TMPF generation of fr-CA Preferred Term (PT)
Format
TMPF-1 (mandatory)
[[ + @ProdName]]1 “ [“ [[ + @AI]] “ ” [[ + @MDF ]] “ ] (” [[ + @Supplier]] 2 “)” 4
TMPF-2 (optional)
[[ + @ProdName]]1 “ [“ [[ + @PAI 5 OR @BOSS 6]] [ “ ( ” [[ + @PAI ]] “)”] 5“ ” [[ + @MDF ]] " ] (” [[ + @Supplier]] 2 “)” 4
Rules for French descriptions
1: ProdName is always fully capitalized
2: Supplier is always fully capitalized
3: For all attribute values, use the fr-CA FSN with no semantic tag
4: For all attribute values, use the en-CA PT
5: PAI is used here when:
- BOSS is a modification of AI (direct or transitive).
- Note: In these cases the PAI = TCD.BOSS
6: “BOSS (as PAI)” is used here when:
- BOSS is NOT a modification of AI (direct or transitive)
Examples of TMPFs
TMPF-1
TMPF-2